<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542643</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH104-REC2-058</org_study_id>
    <nct_id>NCT03542643</nct_id>
  </id_info>
  <brief_title>Omega-3 Polyunsaturated Fatty Acids in Youth With ADHD</brief_title>
  <official_title>A Double-blind Randomised Controlled Trial of N-3 PUFAs in Children With Attention Deficit Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      N-3 polyunsaturated fatty acids(N-3 PUFAs) is important in balancing the immune function and&#xD;
      crucial for the developing brain. Deficiency in n-3 PUFAs might be linked to the poor&#xD;
      cognitive performances resulting in inattention and hyperactivity in youth with attention&#xD;
      deficit hyperactivity disorder (ADHD). N-3 PUFAs appears to be a promising treatment that is&#xD;
      safe, beneficial to youth with ADHD. In this proposal, investigators aim the test the&#xD;
      hypothesis that n-3 polyunsaturated fatty acids will be more effective than placebo in&#xD;
      improving cognitive function in youth with ADHD after 12 weeks of intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 1-year study and a randomized, double-blind, and placebo controlled Clinical the&#xD;
      study. investigators plan to enrol 100 subjects from Child and Adolescent Psychiatry&#xD;
      Outpatient Clinic of China Medical University Hospital.Participants will be randomized into&#xD;
      omega-3 polyunsaturated fatty acids or placebo group.The intervention period is 12 weeks.&#xD;
      Evaluation of the cognitive function ( using Continuous Performance Test 3rd Edition ) of the&#xD;
      subjects who are enrolled into the study will take place at baseline and after the 12th week.&#xD;
      The symptom severity of ADHD will be measured with Swanson, Nolan, Pelham Questionnaire&#xD;
      (SNAP-IV) at baseline, 2,4,8, and 12 weeks. The plasma level of n-3 polyunsaturated fatty&#xD;
      acids, blood and salivary inflammatory markers will also be measured at the beginning and at&#xD;
      the end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2016</start_date>
  <completion_date type="Actual">December 11, 2017</completion_date>
  <primary_completion_date type="Actual">December 11, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Continuous Performance Test Raw Scores at 12 weeks</measure>
    <time_frame>Week 0 and Week 12</time_frame>
    <description>Correct Detection: This indicates the number of times the client responded to the target stimulus. Higher rates of correct detections indicate better attentional capacity.&#xD;
Reaction times: This measures the amount of time between the presentation of the stimulus and the client's response.&#xD;
Omission errors: This indicates the number of times the target was presented, but the client did not respond/click the mouse. High omission rates indicate that the subject is either not paying attention (distractibility) to stimuli or has a sluggish response.&#xD;
Commission errors: This score indicates the number of times the client responded but no target was presented. A fast reaction time and high commission error rate points to difficulties with impulsivity. A slow reaction time with high commission and omission errors, indicates inattention in general.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in SNAP-IV Scores for Inattention, Hyperactivity and Total ADHD Symptom Severity</measure>
    <time_frame>Week 0, 2,4,8,12</time_frame>
    <description>Inattention: items 1-9 Hyperactivity: items 10-18 Total ADHD: items 1-18 the greater the scores on SNAP-IV indicate the greater the severity of ADHD symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Blood PUFAs levels at 12 Weeks</measure>
    <time_frame>Week 0 and Week 12</time_frame>
    <description>measurement of blood PUFAs levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Blood Inflammatory Markers at 12 Weeks</measure>
    <time_frame>Week 0 and Week 12</time_frame>
    <description>measurements of blood inflammatory markers</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Salivary Cortisol at 12 Weeks</measure>
    <time_frame>Week 0 and Week 12</time_frame>
    <description>measurements of salivary cortisol</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>N-3 polyunsaturated fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>n-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>olive oil ethyl esters</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>n-3 Polyunsaturated fatty acid</intervention_name>
    <description>1g of Eicosapentaenoic acid (EPA)</description>
    <arm_group_label>N-3 polyunsaturated fatty acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Olive oil ethyl esters</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-5 diagnosed ADHD&#xD;
&#xD;
          -  Age 6-18 years old at time of enrolment&#xD;
&#xD;
          -  Conner's rating scares (CPRS) with scores &gt;= 2 standard deviations&#xD;
&#xD;
          -  drug native or no medication use for past 6 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intelligence quotient &lt;70&#xD;
&#xD;
          -  Comorbid other psychiatric disorders, such as autism spectrum disorders, anxiety&#xD;
             disorders, conduct disorders, schizophrenia, major depressive disorders and bipolar&#xD;
             spectrum disorders&#xD;
&#xD;
          -  Comorbid physical disorders, such as thyroid dysfunction, cerebral palsy&#xD;
&#xD;
          -  Current using omega-3 supplements&#xD;
&#xD;
          -  Allergy to omega-3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Medical University</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>n-3 polyunsaturated fatty acids</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

